RE: Severance AgreementSeverance Agreement • November 7th, 2018 • Melinta Therapeutics, Inc. /New/ • Pharmaceutical preparations • New York
Effective as of your commencement of employment with Melinta Therapeutics, Inc. (the “Company”), you will be a key member of the senior management team of the Company. As a result, the Company is providing you with the following benefits in consideration of your employment with the Company.
AMENDMENT NO. 2 TO EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENTExclusive License and Development Agreement • November 7th, 2018 • Melinta Therapeutics, Inc. /New/ • Pharmaceutical preparations
This Amendment No. 2 (“Amendment No. 2”) to the EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT, dated as of May 8, 2013 and amended as of September 26, 2013, by and between CEMPRA PHARMACEUTICALS, INC. (“Cempra”) and TOYAMA CHEMICAL CO., LTD. (“Toyama”) is hereby effective as of September 12, 2018. Capitalized terms not defined herein shall have the meaning given to them in the Agreement.
LICENSE AGREEMENT between MELINTA THERAPEUTICS, INC. andLicense Agreement • November 7th, 2018 • Melinta Therapeutics, Inc. /New/ • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”) is entered into and effective as of September 28, 2018 (the “Effective Date”), by and between Melinta Therapeutics, Inc., a company organized and existing under the laws of the State of Delaware, with its principal place of business located at 300 Tri-State International, Suite 200, Lincolnshire, IL 60069, U.S.A. (“Company”), and A. Menarini Industrie Farmaceutiche Riunite S.r.L, a company organized and existing under the laws of Italy, with its principal place of business located at 3, Via Sette Santi, 50131 Florence, Italy (“Licensee”). Company and Licensee are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”
